Maintenance letrozole and abemaciclib for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of uterine cancer called endometrioid endometrial cancer or a related type called carcinosarcoma with an endometrioid part.
- Your cancer has estrogen receptors (ER-positive), meaning at least 1 out of 100 cancer cells test positive for a protein that feeds on estrogen.
- Your tumor does not have a mutation in the TP53 gene (it is 'wild-type'), and your cancer is 'mismatch repair proficient', meaning it has normal DNA repair.
- You have just finished 4 to 10 rounds of chemotherapy that included a taxane drug (like paclitaxel) and either carboplatin or an immunotherapy drug (like pembrolizumab).
- You had advanced or recurrent endometrial cancer that was measurable or visible on scans, and you can start the study pills between 3 and 8 weeks after your last chemo dose.
- You are at least 18 years old, able to swallow pills, and your blood counts and liver/kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This trial tests a new hormone therapy (elacestrant) alone or combined with a targeted pill (abemaciclib) for people with advanced or recurrent endometrial cancer that is hormone-receptor-positive. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.